Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retatrutide in Type 2 Diabetes with Obesity or Overweight (TRIUMPH-2)
NCT05929079Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2023
- Primary completion
- Jun 2026
- Modality
- Peptides, Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of retatrutide in type 2 diabetes mellitus (T2DM), obesity, obstructive sleep apnea (OSA), sponsored by Eli Lilly and Company. Started Jul 2023; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)obesityobstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT05929079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05929079.